Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tg Therapeutics (TGTX) Non-cash Items (2018 - 2024)

Historic Non-cash Items for Tg Therapeutics (TGTX) over the last 6 years, with Q4 2024 value amounting to $3.1 million.

  • Tg Therapeutics' Non-cash Items fell 9338.9% to $3.1 million in Q4 2024 from the same period last year, while for Dec 2024 it was $3.1 million, marking a year-over-year decrease of 9338.9%. This contributed to the annual value of $3.1 million for FY2024, which is 4753.35% up from last year.
  • Per Tg Therapeutics' latest filing, its Non-cash Items stood at $3.1 million for Q4 2024, which was down 9338.9% from $47.6 million recorded in Q4 2023.
  • Tg Therapeutics' 5-year Non-cash Items high stood at $102.5 billion for Q1 2021, and its period low was $3.1 million during Q4 2024.
  • Its 5-year average for Non-cash Items is $21.8 billion, with a median of $115.5 million in 2020.
  • In the last 5 years, Tg Therapeutics' Non-cash Items soared by 264503.55% in 2020 and then crashed by 9338.9% in 2024.
  • Tg Therapeutics' Non-cash Items (Quarter) stood at $115.5 million in 2020, then tumbled by 74.45% to $29.5 million in 2021, then fell by 15.04% to $25.1 million in 2022, then skyrocketed by 89.94% to $47.6 million in 2023, then plummeted by 93.39% to $3.1 million in 2024.
  • Its Non-cash Items stands at $3.1 million for Q4 2024, versus $47.6 million for Q4 2023 and $25.1 million for Q4 2022.